Access to investigational medicines for terminally ill through expanded access programs

Home / Clinical Practice / Access to investigational medicines for terminally ill through expanded access programs

Bottom Line: A new study identified investigational medicines made available through expanded access programs for patients with life-threatening illnesses prior to approval from the U.S. Food and Drug Administration to assess the timing and duration of investigational drug availability.

Authors: Joseph S. Ross, M.D., M.H.S., of Yale University School of Medicine, New Haven, Connecticut, and coauthors

To Learn More: The full study is available on the For The Media website.

(doi:10.1001/jamanetworkopen.2018.0283)

Editor’s Note: The article contains conflict of interest and funding support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

###

Leave a Reply

Your email address will not be published.